NovoCure Limited filings document the oncology device company's operating results, product and regulatory updates, and governance for its Tumor Treating Fields business. Recent Form 8-K reports include quarterly and annual financial results, FDA approval disclosure for Optune Pax, clinical-trial updates for pancreatic cancer, Medicare billing-status disclosure and executive compensatory arrangements.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. The filing record also identifies NovoCure as a Jersey-incorporated registrant under the Nasdaq ticker NVCR and records formal disclosures tied to its commercial products, clinical programs and reimbursement matters.
Soleus Capital group reports shared beneficial ownership of 10,492,391 ordinary shares of NovoCure Limited, representing 9.1% of the class. The percentage is calculated using 115,820,940 ordinary shares outstanding as of April 24, 2026, per the issuer's Form 10-Q cover. The filing lists the Master Fund and affiliated entities (Soleus Capital, SCG, SCM, Soleus GP) and Guy Levy as reporting persons and disclaims individual beneficial ownership except for Section 13(d) purposes.
Novocure reported first-quarter 2026 net revenues of $174.1 million, up 12% year over year, driven mainly by growth in European Optune Gio patients and contributions from Optune Lua and the Zai Lab partnership in Greater China. Gross margin improved to 78% from 75% as array costs fell.
Higher operating expenses led to a wider net loss of $71.1 million, or $0.62 per share, largely due to a $43 million non-cash share-based compensation charge tied to U.S. FDA approval of Optune Pax. Adjusted EBITDA was slightly negative at $0.3 million.
The company ended March 31, 2026 with $432.0 million in cash, cash equivalents and short-term investments and 4,791 active TTFields patients globally. Regulatory and clinical momentum included U.S. FDA approval and U.S. launch of Optune Pax for locally advanced pancreatic cancer, new coverage decisions in Czechia, British Columbia and Japan, and positive Phase 2 PANOVA-4 data in metastatic pancreatic cancer. Novocure raised 2026 revenue guidance to $690–$710 million and tightened Adjusted EBITDA guidance to a range of $(15) million to breakeven.
NovoCure Limited reported higher revenue but a wider loss for the quarter ended March 31, 2026. Net revenues rose 12% to $174.1 million, driven mainly by international growth in Germany, France and other markets, plus increased U.S. usage of Optune Gio and Optune Lua.
Gross margin improved to 78% as cost per active patient fell, but operating expenses climbed on new indication launches and higher share-based compensation. The company recorded a net loss of $71.1 million, or $0.62 per share, compared with a $34.3 million loss a year earlier.
Adjusted EBITDA narrowed to a small loss of $0.3 million. Active patients on therapy increased to 4,791, supported by the U.S. launch of Optune Pax for locally advanced pancreatic cancer and ongoing expansion of Optune Lua for NSCLC. Cash, cash equivalents and short-term investments totaled $432.0 million, and 115,820,940 ordinary shares were outstanding as of April 24, 2026.
NovoCure Ltd director Vernon W. Anthony exercised stock options to acquire 21,500 Ordinary Shares at $11.39 per share. These were option exercises rather than open-market purchases or sales. After the transactions, he directly holds 200,602 Ordinary Shares, and the exercised option grant for 21,500 shares has been fully used.
Novocure Ltd ownership filing shows Vanguard Portfolio Management beneficially owned 6,339,994 shares of common stock, representing 5.57% of the class as of 03/31/2026. The filer reports 88,293 shares with sole voting power and 6,339,994 shares with sole dispositive power. The filing is signed by Ashley Grim on 04/28/2026.
NovoCure Limited filed an amendment to a prior report to describe the compensation package for its new Chief Executive Officer, Frank Leonard, whose appointment became effective December 1, 2025. A new employment agreement, effective January 1, 2026, sets an annual base salary of CHF 750,000 and a discretionary annual cash bonus targeted at 90% of base salary, based on performance goals set by the Board.
Leonard is eligible for equity awards under the 2024 Omnibus Incentive Plan and broad executive benefits, including relocation reimbursement from the U.S. to Switzerland and six months of COBRA reimbursements, each grossed up for taxes. He also receives tax indemnification if U.S. federal and Pennsylvania authorities do not fully credit Swiss tax payments. If terminated without cause or if he resigns for good reason before a change in control, he is entitled to one year of base salary paid in installments. If such a termination occurs within 12 months after a change in control, he is entitled to a lump sum of 200% of base salary plus 200% of target bonus, and all equity awards will fully vest. The agreement includes perpetual non-disparagement and 12‑month post-employment confidentiality, non-compete, and non-solicitation covenants.
NovoCure Limited is asking shareholders to vote at its June 3, 2026 annual meeting on four main items: electing 11 directors for one-year terms, ratifying EY Global as auditor for 2026, approving a non-binding Say-on-Pay vote, and amending its 2024 Omnibus Incentive Plan.
The amended plan would increase the share reserve by 9,000,000 Ordinary Shares, extend the plan’s term to 2036, remove liberal share recycling, and introduce a general one-year minimum vesting requirement, with limited exceptions. As of the April 6, 2026 record date, NovoCure had 115,820,940 Ordinary Shares outstanding, 2,879,680 shares remaining available under the current plan, and 21,234,241 shares subject to outstanding awards, implying total overhang of 22.2% if the increase is approved.
The company highlights 2025 progress: $655 million in net revenue (up 8%), 4,620 active TTFields patients (up 12%), 7,035 prescriptions (up 9%), key Phase 3 PANOVA-3 and METIS trial successes leading to FDA submissions, and cash, cash equivalents and short-term investments of $448 million at year-end. The Board reports strong independence, diversity metrics, and broad-based equity participation, and recommends voting FOR all proposals.
NovoCure Limited reported a change to executive compensation as Uri Weinberg, M.D., Ph.D. takes on the additional role of Chief Medical Officer while continuing as Chief Innovation Officer. Under a letter agreement dated April 7, 2026, he will receive a stipend increasing his salary by CHF 5,000 per month for as long as he serves as Chief Medical Officer. The company states this additional amount is tied solely to the extra assignment and will not be included when calculating his annual incentive payment, while all other employment terms remain unchanged.
The Vanguard Group filed an amendment to a Schedule 13G/A reporting beneficial ownership of 0 shares of Novocure Ltd Common Stock, representing 0% of the class.
The filing states that on January 12, 2026 Vanguard completed an internal realignment and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim and dated 03/26/2026.
Novocure reported positive topline Phase 2 PANOVA-4 results for Tumor Treating Fields (TTFields) used with atezolizumab, gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic ductal adenocarcinoma.
The regimen achieved a disease control rate of 74.4% in 78 patients, compared with 48% in 431 patients receiving gemcitabine and nab-paclitaxel alone in a historical Phase 3 control, a 26.4% difference with strong statistical significance (1-sided p < 0.001). Objective response rate was 34.6% and median overall survival was 9.7 months. Treatment duration and safety for TTFields were consistent with prior studies, and the company plans to present additional data at a future scientific forum.